Cytori Therapeutics Inc. (NASDAQ:CYTX) saw an uptick in trading volume on Tuesday . 166,550 shares were traded during trading, an increase of 21% from the previous session’s volume of 137,975 shares.The stock last traded at $2.09 and had previously closed at $2.05.

Several equities research analysts have recently weighed in on CYTX shares. Maxim Group reaffirmed a “buy” rating and set a $75.00 price target on shares of Cytori Therapeutics in a research report on Thursday, March 31st. Roth Capital began coverage on Cytori Therapeutics in a research note on Monday, March 28th. They issued a “buy” rating and a $22.50 target price on the stock. Finally, Zacks Investment Research upgraded Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a research note on Tuesday, July 12th.

The company’s 50-day moving average is $2.16 and its 200-day moving average is $2.86. The firm’s market capitalization is $28.00 million.

Cytori Therapeutics (NASDAQ:CYTX) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.38. During the same period in the previous year, the company posted ($0.07) earnings per share. The firm earned $2.90 million during the quarter, compared to analyst estimates of $2.05 million. The firm’s quarterly revenue was up 26.1% on a year-over-year basis. Equities research analysts predict that Cytori Therapeutics Inc. will post ($1.59) EPS for the current fiscal year.

Cytori Therapeutics, Inc (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns combined with radiation injury.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.